Earnings Releases·Nov 4, 2026, 4:11 PM ET

Evolus — Third Quarter 2026 Earnings Summary

Q3 2026 total net revenue reached $78.0 million, up 13% year-over-year, driven by 11% growth in global toxin revenue and nearly 40% growth in injectable hyaluronic acid (HA) gel revenue; GAAP operating loss narrowed to $8.4 million from $11.5 million in Q3 2025, while Adjusted EBITDA turned positive at $1.2 million, marking the fourth consecutive quarter of profitability.
Management reaffirmed full-year 2026 total net revenue guidance of $330 million to $337 million and adjusted gross profit margin guidance of 67.0% to 67.5%, while updating non-GAAP operating expense guidance to $210 million to $213 million; long-term 2028 outlook targets revenue between $450 million and $500 million with an Adjusted EBITDA margin of 13% to 15%.
Strategic expansion includes an exclusive agreement with IBSA to commercialize Profhilo® in the U.S., an option agreement for a first-in-class hair growth product, and anticipated U.S. FDA approval for Evolysse® Sculpt in Q4 2026, alongside the commercialization of Evolysse® Form, Smooth, and the Estyme® collection in Europe.
The company holds approximately $120 million in additional non-dilutive capacity and $41.7 million in cash as of September 30, 2026, while proactively securing 12 months of Jeuveau® inventory ahead of potential tariffs, with no expected impact on cash flow due to a deferred payment agreement with Daewoong.